Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label pharmacokinetic interaction study of cannabidiol with clobazam, stiripentol, or valproate in healthy adults
NL-OMON43875Phase 1Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cannabidiol, clobazam, stiripentol and valproic acid in epilepsy (6 cohorts), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Effect of multiple-dose cannabidiol on steady-state plasma concentrations of clobazam, stiripentol, or valproate and Effect of multiple-dose clobazam, stiripentol, or valproate on steady-state plasma concentrations of cannabidiol. Started Nov 2015; status: active, not recruiting.
02
Drugs
cannabidiolclobazamstiripentolvalproic acid
03
Conditions
epilepsy
Beyond the preview
Go deeper on NL-OMON43875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43875.